ArticleBMJ open2026

Cost-effectiveness of sugemalimab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced oesophageal squamous cell carcinoma in China.

Chunyan Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.